Expanded possibilities for laboratory digitalization and connectivity: labforward merges with LabTwin
September 19, 2024Business Services, Research and Development AI, Corporate, LabTwin, laboratory
The two Berlin-based companies labforward and LabTwin, a subsidiary of the life science group Sartorius, are merging in order to …
Steriline’s founder “passes torch” to children with CEO and CSO appointments
September 19, 2024Corporate, Steriline
Aseptic packaging company Steriline’s founder Gerardo Fumagalli has “passed the torch” to his children Illaria Fumagalli and Federico Fumagalli, who …
Butterfly Network Expands its Next-Generation Butterfly iQ3™ to Europe
September 11, 2024Butterfly Network, medical imaging
Butterfly iQ3 is built on the next-generation Ultrasound-on-Chip™ technology featuring unparalleled image quality, new 3D imaging capabilities, and a smaller, …
Chiesi Global Rare Diseases Launches New Research Grant Initiative to Support Research Excellence in Lysosomal Storage Disorders
September 9, 2024Research and Development Rare Diseases
9 September 2024, –London, UK –Applications for the independently assessed, expert-led Research Grant Initiative, Find For Rare, are open from …
Amferia closes €1,2 million investment to combat resistant bacterial infections
September 3, 2024Research and Development Amferia, Chalmers Ventures, Dressings, hosiery & appliances, Hospital Management, Immunology, antimicrobial, investment, peptides
Swedish medtech company Amferia announces the successful completion of its latest investment round, boosting its mission to combat wound infections. …
The National Institute for Health and Care Excellence announce technology appraisal guidance recommending risankizumab for adult patients with moderate to severe ulcerative colitis
August 29, 2024Research and Development AbbVie, Crohns, Gastrointestinal tract, Immunology, NICE, approval, ulcerative colitis
The National Institute for Health and Care Excellence (NICE) have recommended adult patients in England or Wales with moderately or …
Leadership Appointments at RQM+
August 28, 2024Research and Development AI and ML, Corporate, RQM+, appointment
Ronnie Mahofski and Kevin Rowland both become Executive Vice President and General Manager On August 27, MedTech service provider RQM+ announced …
European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients
August 27, 2024Research and Development J&J, Oncology, chemotherapy, non-small cell lung cancer
Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission (EC) has approved a combined …
New gastric & gastro-oesophageal junction cancer treatment VYLOY™ ▼ (zolbetuximab): the first claudin 18.2 biomarker targeted therapy licensed in Great Britain
August 16, 2024GEJ cancers, Gastrointestinal tract, MHRA, Oncology, gastric cancer
Claudin18.2 is an innovative drug-target which is not currently used for any other authorised treatment. There is a large unmet …
First oral treatment for hormone-sensitive prostate cancer recommended by NICE
August 15, 2024Research and Development Accord healthcare, Oncology, Reproductive health, hormone-sensitive, prostate cancer
Today, Accord Healthcare has announced that the National Institute for Health and Care excellence (NICE) have recommended the first oral …
FDA approves drug for primary biliary cholangitis
August 15, 2024Research and Development FDA Approval, FDA approva;, Hepatology, liver, primary biliary cholangitis
Accelerated approval has been granted for Gilead Science’s Livdelzi (seladelpar) to treat primary biliary cholangitis (PBC) by the US Food …
Kerato Ltd Partners with University of Montreal to develop novel treatment for corneal damage
August 14, 2024Research and Development Kerato, Opthalmology, University of Montreal, corenas
BSF the Main Market listed biotech company and owner of corneal tissue replacement company Kerato Ltd, is pleased to announce …
David Wheadon appointed to board of directors at Seaport Therapeutics
August 14, 2024Corporate, Seaport Therapeutics, appointment
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.
Verisense announce opening of Digital Biobank
August 14, 2024Research and Development AI, Devices, Diagnostics, Verisense, artificial intelligence, digital health, machine learning
This week, Verisense have announced that their Digital Biobank, with data from over one million people, is open for business.
China CDE clears Phase 3 Study of Lisafltoclax in Newlly Diagnosed Patients with Higher-Risk Myelodysplastic Syndrome
August 13, 2024Clinical Research, Research and Development Ascentage Pharma, Oncology
The China Centre for Drug Evaluation (CDE) has cleared the registrational phase 3 study of lisaftoclax in combination with azacitadine …
Pfizer releases results for severe RSV-associated LRTD treatment study
August 13, 2024Clinical Trial Services, Research and Development Immunology, Pfizer, autoimmune, clinical trial, respiratory, vaccines
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical trial into the safety and …
First Nasal Spray for Treatment of Anaphylaxis approved by FDA
August 12, 2024Research and Development Emergency Medicine, FDA, anaphylaxis, epinephrine, nasal
ARS Pharmaceuticals has been granted approval by the US Food and Drug Administration (FDA) for their epinephrine nasal spray, neffy, …
Merck to acquire Curon Biopharmaceutical’s B-Cell Depletion Therapy
August 12, 2024Research and Development Corporate, Curon Biopharmaceuticals, Merck, Oncology, b-cells
Merck have announced that they have entered into an agreement with private biotechnology company Curon Biopharmaceuticals to acquire CN201, a …
Richmond promotes new Director of Communications and Participant Engagement
August 9, 2024Research and Development Corporate, Richmond Pharmacology, appointment, pharmaceutical
Richmond Pharmacology is delighted to announce the promotion of Liz Romano to the new position of Director of Communications and …
Janssen’s study for nipocalimab as indicated for EOS-HDFN published in The New England Journal of Medicine
August 9, 2024Research and Development Haematology, Janssen, New England Journal of Medicine, Obstetrics & Gynaecology, foetus, newborn, women's health
Johnson & Johnson company Janssen has announced that the results from its phase 2 trial into nipocalimab have been published …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
